Alcides José Zago

Erectile Dysfunction and Coronary Artery Disease: An Association of Higher Risk in Younger Men

INTRODUCTION The association between erectile dysfunction (ED) and coronary artery disease (CAD) has been described in various settings, but it is unclear if there is an independent interaction with age. AIM To investigate the interaction of age in the association between ED and CAD. METHODS This case-control study was conducted among 242 patients referred for elective coronary angiography. One hundred fourteen patients with significant CAD were identified as cases and 128 controls without significant CAD. ED was evaluated by the erectile function domain of the International Index of Erectile Function (IIEF) questionnaire, determined by a score ≤ 25 points. MAIN OUTCOME MEASURES Significant CAD was based on stenosis of 50% or greater in the diameter in at least one of the major epicardial vessels or their branches. The analysis was conducted in the whole sample and according to the age strata, controlling for the effects of cardiovascular risk factors, testosterone, and C-reactive protein. Results.  Patients had on average 58.3 ± 8.9 years. CAD and ED were associated exclusively in patients younger than 60 years (ED in 68.8% of patients with CAD vs. 46.7% of patients without CAD, P = 0.009). The association was independent of cardiovascular risk factors, testosterone and C-reactive protein (risk ratio 2.3, 95% confidence interval from 1.04 to 5.19). Severity of CAD was higher in patients younger than 60 years with ED. CONCLUSIONS Men with less than 60 years of age who report ED presented a higher risk of having chronic CAD and more severe disease diagnosed by coronary angiography.

Endothelial Dysfunction and Coronary Artery Disease

For several decades, the vascular endothelium was considered a unicellular layer acting as a semipermeable membrane between the blood and the interstitium. Recently, it has been demonstrated that the endothelium performs a large range of important biological functions, participating in several metabolic and regulatory pathways. Along with long-known specialized functions like gaseous exchange in the pulmonary circulation and phagocytosis in the hepatic and splenic circulation, the vascular endothelium performs universal roles in the circulation that include participation in thrombosis and thrombolytic control, vascular growth, platelet and leukocyte interactions with the vascular wall, and vasomotor tone. The study of endothelium-dependent vasomotor reactivity has produced over the years, scientific evidence fundamental for the understanding of the endothelium’s role in physiological and pathological situations. In 1977, Moncada et al, published the first report indicating that the endothelium plays a central role in the control of vascular tone via the production of vasoactive substances . In 1980, Furchgott and Zawadzki 2 demonstrated in an experimental preparation of the rabbit aorta, the obligatory role played by endothelial cells in vascular relaxation in response to effectors like acetylcholine, and postulated the existence of a vascular relaxing factor derived from the endothelium. In 1987, two research groups, lead by Ignarro et al , and by Palmer et al , demonstrated that the relaxing factor derived from the endothelium was nitric oxide, an odorless gas until then considered as a mere pollutant. Endothelial dysfunction was first characterized in humans in 1986 by Ludmer et al, 5 who demonstrated that atherosclerotic coronary arteries contracted in response to intracoronary infusion of acetylcholine, while normal coronaries showed dilatation. In 1992, endothelial dysfunction was documented by Celermajer et al 6 in children and otherwise healthy young adults with risk factors for atherosclerosis. Under physiological conditions, the endothelium keeps a reduced vasomotor tone, prevents leukocyte and platelet adhesion, and inhibits the proliferation of vascular smooth muscle cells. In contrast, endothelial dysfunction appears to play a pathogenic role in the initial development of atherosclerosis 7-9 and of unstable coronary syndromes , being associated with atherosclerotic disease risk factors , and being present even before vascular involvement becomes evident . Recent clinical studies have demonstrated that some drugs well known to reduce the incidence of cardiovascular events, improve endothelial function . On the other hand, clinical interventions like the continuous administration of organic nitrates and percutaneous coronary interventions may be associated with adverse effects on the vascular endothelium. In the present article, we will discuss vascular endothelial function versus dysfunction, and their impact on cardiovascular disease, in particular atherosclerosis.

Thoracic endovascular aortic repair – a Brazilian experience in 255 patients over a period of 112 months

The aim of this study is to analyze the immediate and late evolution for death and reintervention in a thoracic endovascular aortic repair (TEVAR) group, over a follow-up period of 112 months. Retrospective data of 255 patients, from 1998 to 2007, were obtained. The most prevalent diseases were thoracic aortic aneurysms (89), thoracic and abdominal aneurysms (85) and thoracic aortic dissections (61). The mean age was 63.2 years and 67.1% were male. Three hundred and three endoprostheses were used. Causes of morbidity, in the immediate postoperative period, were hyperthermia (45.9%), endoleaks (9.8% - being 7.1% type I), vascular complications (5.2%), renal insufficiency (3.1%) and neurological complications (3.1%). There were two (0.8%) hospital deaths and 17 (6.7%) late deaths. Time of follow-up was up to 112 months (mean of 60 months). The Kaplan-Meier curve analysis showed an increase of reintervention, compared with death, after a follow-up period of 42 months. Freedom from death at 36, 60 and 112 months was 96%, 89.1%, 85.1% and for reintervention, for the same periods was 93.6%, 82.7%, 57.2%, respectively. This study showed low incidence of prostheses related morbidity and immediate mortality. After a period of 42 months there was an increase on the percentual tax of reintervention.

Tratamento endovascular dos aneurismas de aorta abdominal: experiência inicial e resultados a curto e médio prazo

Objective: The purpose of this study is to present the short and medium-term results of the endovascular treatment of abdominal aortic aneurysms (AAAs). This is an initial experience of a multidisciplinary team. Method: Between July 2003 and October 2005, 42 patients (25 of whom suffered from AAAs) were treated with endovascular therapy for aortic diseases. The mean patient age was 74 ± 10.2 years with 92% men. The endovascular procedures were performed by a multidisciplinary team in the Hospital de Clinicas de Porto Alegre and Hospital Luterano (ULBRA). In twenty-four of the AAA patients, bifurcated grafts were used and only one had a straight graft. In all patients the procedure was carried out by femoral artery dissection in a catheterization laboratory. There was no need to convert to open repair. Results: There were no operative or postoperative deaths. The survival rate free from re-interventions is 96% after two years and three months. One (4%) patient needed a new endovascular procedure for a type I endoleak one year after, and three extensions were used successfully. Two other patients needed femoro-femoral bypasses, one at the same time as the endovascular procedure and the other one 24 hours later because of lower limb ischemia. Conclusion: The endovascular treatment of AAAs represents a new less invasive alternative to conventional surgery, especially for high risk patients. Further prospective and randomized studies to evaluate the long term outcomes are needed. Excellent results in the short and medium-terms can be obtained by multidisciplinary teams in our country.

Endovascular repair of an abdominal aortic aneurysm in patient with horseshoe kidney: a case report

Horseshoe kidney is a rare congenital anomaly that may cause various technical problems during conventional repairs of abdominal aortic aneurysms. We report the case of a 68-year-old woman with a horseshoe kidney, symptomatic abdominal aortic aneurysm and mild renal failure. The patient underwent endovascular repair using a bifurcated endoprosthesis. The postoperative was uneventful. We describe the diagnosis and the endovascular technique and literature review.

Hemodynamic effects of sildenafil in patients with stable ischemic heart disease

BACKGROUND Recently the new specific phosphodiesterase-5 inhibitor sildenafil was introduced into therapy for erectile dysfunction. The hemodynamic effects of sildenafil may be potentially hazardous for patients with cardiac disease. Sildenafil has been reported to augment the hypotensive effects of nitrates. There is sparse information regarding the systemic and pulmonary hemodynamic effects of a single oral dose of sildenafil in patients with stable angina. METHODS Male patients referred for coronary angiography with diagnosis of chronic stable angina were enrolled in this study to assess the acute hemodynamic effects of sildenafil. Patients receiving long-acting or sublingual nitrates for the last 6 h before the study were excluded. Hemodynamic measurement were taken during right and left heart catheterization in the basal state and 60 min after 50 mg of oral sildenafil. RESULTS Twelve patients (age 53+/-7 years) were studied. All had stable angina CCS class II or III. Four had previous myocardial infarction. By coronary angiography, seven patients had at least one coronary artery with >70% stenosis, four had at least one with 50-70% stenosis, and one had only intimal irregularities. There were no significant effects of sildenafil on systemic or pulmonary arterial pressure, left ventricle end diastolic pressure, cardiac output, and systemic or pulmonary vascular resistance (P>0.05 for all). No adverse events were observed. CONCLUSION A single oral dose of sildenafil had no significant hemodynamic effect in supine patients with stable angina. Isolated administration of sildenafil does not appear to be associated to adverse cardiovascular effects.

Does serum ferritin correlate with coronary angiography findings

BACKGROUND A number of epidemiological studies have described a positive relationship between serum ferritin levels and coronary heart disease. In this prospective study, we evaluated the association between serum ferritin levels and the angiographic extent of coronary atherosclerosis. METHOD We studied 307 consecutive patients (60.9% male, age 60.1+/-11.0 years) referred for diagnostic coronary angiography. Risk factors for coronary artery disease, lipids and ferritin levels, as well clinical characteristics were recorded from all patients. Two experienced cardiologists blinded for clinical and laboratory data reviewed the cinefilms. Angiographic significant coronary artery disease (CAD) was defined as any more than a 50% diameter stenosis. RESULTS From the 307 patients, 196 (63.8%) were found to have angiographic significant CAD. The presence of significant CAD was associated with ferritin levels (P=0.015) as well as patient age (P<0.001), male sex (P<0.001), smoking (P<0.002), and cholesterol levels (P=0.028). By multivariate analysis, however, ferritin level was not an independent risk factor for CAD (P=0.27), while the association with all the other factors remained significant. CONCLUSION In patients referred for coronary angiography no independent relationship was found between angiographic significant coronary artery disease and serum ferritin levels.

Left ventricular function and endomyocardial biopsy in early and advanced dilated cardiomyopathy

We evaluated left ventricular function and endomyocardial biopsy in 20 patients with early and advanced dilated cardiomyopathy, with the purpose of assessing the correlation between histologic variables and systolic and diastolic filling indexes. Group 1 included 10 patients with no clinical history of heart failure and left ventricular ejection fraction > or = 45% and group 2, 10 patients with a clinical history of heart failure and left ventricular ejection fraction <45%. Group 1 showed lower left ventricular end-systolic and end-diastolic volumes indexes (49+/-14 versus 86+/-23 ml/m2, P<0.001; 98+/-25 versus 127+/-35 ml/m2, P=0.049), higher left ventricular ejection fraction (50+/-4 versus 32+/-4%, P<0.001) and lower coefficient of variation of percentage shortening of left ventricular transverse hemiaxes (0.3+/-0.1 versus 0.5+/-0.1, P=0.001) compared with group 2. Group 1 had higher A wave peak velocity (78+/-18 versus 60+/-20 cm/s, P=0.048), lower E/A ratio (0.9+/-0.3 versus 1.5+/-0.6, P=0.02) and slower E wave deceleration time (204+/-51 versus 155+/-50 ms, P=0.047) compared with group 2. Semiquantitative histologic scores did not differ significantly between groups. There was no significant correlation between histologic variables and left ventricular systolic and diastolic indexes. Thus, dilated cardiomyopathy shows borderline to severe left ventricular systolic impairment and distinct left ventricular diastolic filling abnormalities, according to the clinical stage. This study suggests a marked dissociation between histologic findings and functional abnormalities in early and advanced dilated cardiomyopathy.

Racional e desenho do registro brasileiro de implante de bioprótese aórtica por cateter

BACKGROUND: Surgical replacement of the aortic valve is the therapy of choice for patients with severe aortic stenosis. However, the surgical risk increases dramatically as age advances and with the association of comorbidities. Recently, transcatheter aortic valve implantation has been introduced in Brazil. Therefore, it was important to create a national registry to determine the outcomes of this procedure in our country. The rationale and design of the Brazilian Transcatheter Aortic Valve Implantation Registry is described. METHODS: This is a multicenter prospective registry, including 200 patients with symptomatic aortic valve stenosis and high surgical risk submitted to transcatheter aortic valve implantation in Brazilian institutions. The primary endpoint of the study is all cause mortality at 30 days, 12 and 24 months. Secondary endpoints, among others, are: 1) technical success of transcatheter valve implantation; 2) cardiovascular mortality at 30 days, 12 and 24 months; 3) composite safety endpoint at 30 days; and 4) composite efficacy endpoint at 12 and 24 months. CONCLUSIONS: The analysis of the results of this national registry will enable us to evaluate the outcomes of transcatheter aortic valve implantation in our country.

Endovascular repair of ascending aorta and coronary stent implantation

Endovascular treatment of ascending aorta pseudoaneurysms with coronary stents implantation at the same procedure was feasible, although longer followup is necessary.